OPK · Opko Health, Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OPK
this stock
Opko Health, Inc.
|
$1.10B | +16.7% | -14.9% | — | 4.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$230.05B | +6.5% | +14.5% | 33.5 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.09B | -6.7% | +8.5% | 37.1 | 1.2% |
|
NTRA
Natera, Inc.
|
$47.03B | +40.5% | -2.8% | — | 3.0% |
|
IQV
Iqvia Holdings Inc.
|
$43.12B | +15.9% | +41.6% | 32.1 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OPK | -0.7% | +12.2% | +23.5% | +11.4% | +16.7% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -1.2% | +11.0% | +10.3% | +8.7% | +4.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.